A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17.
Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide.
Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks.
There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Inclusion Criteria:
Exclusion Criteria:
abbvieclinicaltrials@abbvie.com844-663-3742
Huntsville, Alabama 35805-4046, United States
Saraland, Alabama 36571, United States
Long Beach, California 90807, United States
Fort Collins, Colorado 80528, United States
Gulf Breeze, Florida 32561-4495, United States
Homestead, Florida 33030-4613, United States
Spring Hill, Florida 34609-5692, United States
Newburgh, Indiana 47630, United States
Overland Park, Kansas 66210-2761, United States
Ann Arbor, Michigan 48104-5131, United States
Papillion, Nebraska 68046-4131, United States
Cincinnati, Ohio 45215-2123, United States
Cincinnati, Ohio 45229, United States
Philadelphia, Pennsylvania 19104-4319, United States
Austin, Texas 78723-3079, United States
London, Ontario N6A 5W9, Canada
Beer Ya'akov, Central District 70300, Israel
Palermo, 90127, Italy
Sendai, Miyagi 982-0014, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Poznan, Greater Poland Voivodeship 60-848, Poland
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-752, Poland
Krakow, Lesser Poland Voivodeship 30-539, Poland
Lublin, Lublin Voivodeship 20-582, Poland
Wroclaw, 52-210, Poland
Cluj-Napoca, Cluj 400012, Romania
London, Greater London WC1N 3HZ, United Kingdom
760-758-2222
850.934.1299
770-376-7912
812-474-7184
734-677-6000
601-790-1811
716-558-5670
513-791-7760
405-447-8839
915-598-8888
281-218-8080
+45 50935730
787-797-1049